Literature DB >> 19760920

KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.

Keming Zhang1, Wei Tang, Xianjun Qu, Qian Guo, Yoshinori Inagaki, Yasuji Seyama, Hideki Abe, Ruoyan Gai, Norihiro Kokudo, Yasuhiko Sugawara, Munehiro Nakata, Masatoshi Makuuchi.   

Abstract

BACKGROUND/AIMS: KL-6 mucin is MUC1 bearing sialylated carbohydrate epitopes recognized by KL-6 antibody. This study aimed to assess subcellular localization of KL-6 mucin in liver metastatic tissues from colorectal carcinoma and hepatocellular carcinoma tissues.
METHODOLOGY: Tissue samples were collected from 56 patients with liver metastasis of colorectal carcinoma and 92 patients with hepatocellular carcinoma who underwent a hepatectomy. Tissues were subjected to immunohistochemical analysis using KL-6 antibody.
RESULTS: All 56 cases with metastatic liver cancer showed positive staining for KL-6 mucin in cancer tissues but not in non-cancerous tissues. All staining was observed in the circumferential membrane and/or cytoplasm of the cancer cells. In contrast, no staining for KL-6 mucin was observed in either cancerous or non-cancerous tissues of the 92 patients with hepatocellular carcinoma.
CONCLUSIONS: KL-6 mucin may be an indicator for liver metastasis of colorectal carcinoma. Additionally, detection of KL-6 mucin may be helpful in distinguishing hepatocellular carcinoma from metastatic liver cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760920

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

Review 1.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 2.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

3.  LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Authors:  Carl Christoph Schimanski; Markus Möhler; Michael Schön; Eric van Cutsem; Richard Greil; Wolf Otto Bechstein; Susanna Hegewisch-Becker; Götz von Wichert; Matthias Vöhringer; Michael Heike; Volker Heinemann; Marc Peeters; Stephan Kanzler; Stefan Kasper; Friedrich Overkamp; Jan Schröder; Daniel Seehofer; Frank Kullmann; Bernhard Linz; Irene Schmidtmann; Victoria Smith-Machnow; Ines Gockel; Hauke Lang; Peter R Galle
Journal:  BMC Cancer       Date:  2012-04-11       Impact factor: 4.430

4.  Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery.

Authors:  Zhi-Gang Sun; Min Zhang; Fei Yang; Wei Gao; Zhou Wang; Liang-Ming Zhu
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

5.  Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).

Authors:  Carl Christoph Schimanski; Stefan Kasper; Susanna Hegewisch-Becker; Jan Schröder; Friedrich Overkamp; Frank Kullmann; Wolf Otto Bechstein; Matthias Vöhringer; Robert Öllinger; Florian Lordick; Volker Heinemann; Michael Geißler; Armin Schulz-Abelius; Helga Bernhard; Michael R Schön; Richard Greil; Peter Galle; Hauke Lang; Irene Schmidtmann; Markus Moehler
Journal:  Oncoimmunology       Date:  2020-08-23       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.